Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C18H20FN3O4 |
Molecular Weight | 361.3675 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@H]1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2N4CCN(C)CC4
InChI
InChIKey=GSDSWSVVBLHKDQ-JTQLQIEISA-N
InChI=1S/C18H20FN3O4/c1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21/h7-8,10H,3-6,9H2,1-2H3,(H,24,25)/t10-/m0/s1
Molecular Formula | C18H20FN3O4 |
Molecular Weight | 361.3675 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Levofloxacin is the L-isomer of the racemate, ofloxacin, a quinolone antimicrobial agent. Levofloxacin is used for oral and intravenous administration. Levofloxacin is sold under brand name levaquin and is used to treat infections in adults (≥18 years of age) caused by designated, susceptible bacteria such as, pneumonia: nosocomial and community acquired; skin and skin structure infections: complicated and uncomplicated; chronic bacterial prostatitis; inhalational anthrax. In addition this drug is used to treat plague; urinary tract infections: complicated and uncomplicated; acute pyelonephritis; acute bacterial exacerbation of chronic bronchitis and acute bacterial sinusitis. Levofloxacin, like other fluoroquinolones, inhibits the bacterial DNA gyrase, halting DNA replication. This results in strand breakage on a bacterial chromosome, supercoiling, and resealing. In addition, levofloxacin inhibits a bacterial type II topoisomerase.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14506016
Curator's Comment: levofloxacin penetrates the cerebrospinal fluid (CSF) during meningeal inflammation both in animals and in humans
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2363033 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26525786 |
|||
Target ID: CHEMBL2311225 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26459538 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | LEVAQUIN Approved UseLEVAQUIN is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria. Pneumonia: nosocomial and community acquired; skin and skin structure infections: complicated and uncomplicated; chronic bacterial prostatitis; inhalational anthrax. Post-Exposure and plague; urinary tract infections: complicated and uncomplicated; acute pyelonephritis; acute bacterial exacerbation of chronic bronchitis and acute bacterial sinusitis. Launch Date1996 |
|||
Curative | LEVAQUIN Approved UseLEVAQUIN is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria. Pneumonia: nosocomial and community acquired; skin and skin structure infections: complicated and uncomplicated; chronic bacterial prostatitis; inhalational anthrax. Post-Exposure and plague; urinary tract infections: complicated and uncomplicated; acute pyelonephritis; acute bacterial exacerbation of chronic bronchitis and acute bacterial sinusitis. Launch Date1996 |
|||
Curative | LEVAQUIN Approved UseLEVAQUIN is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria. Pneumonia: nosocomial and community acquired; skin and skin structure infections: complicated and uncomplicated; chronic bacterial prostatitis; inhalational anthrax. Post-Exposure and plague; urinary tract infections: complicated and uncomplicated; acute pyelonephritis; acute bacterial exacerbation of chronic bronchitis and acute bacterial sinusitis. Launch Date1996 |
|||
Curative | LEVAQUIN Approved UseLEVAQUIN is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria. Pneumonia: nosocomial and community acquired; skin and skin structure infections: complicated and uncomplicated; chronic bacterial prostatitis; inhalational anthrax. Post-Exposure and plague; urinary tract infections: complicated and uncomplicated; acute pyelonephritis; acute bacterial exacerbation of chronic bronchitis and acute bacterial sinusitis. Launch Date1996 |
|||
Curative | LEVAQUIN Approved UseLEVAQUIN is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria. Pneumonia: nosocomial and community acquired; skin and skin structure infections: complicated and uncomplicated; chronic bacterial prostatitis; inhalational anthrax. Post-Exposure and plague; urinary tract infections: complicated and uncomplicated; acute pyelonephritis; acute bacterial exacerbation of chronic bronchitis and acute bacterial sinusitis. Launch Date1996 |
|||
Curative | LEVAQUIN Approved UseLEVAQUIN is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria. Pneumonia: nosocomial and community acquired; skin and skin structure infections: complicated and uncomplicated; chronic bacterial prostatitis; inhalational anthrax. Post-Exposure and plague; urinary tract infections: complicated and uncomplicated; acute pyelonephritis; acute bacterial exacerbation of chronic bronchitis and acute bacterial sinusitis. Launch Date1996 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
7.9 mg/L |
500 mg 2 times / day multiple, intravenous dose: 500 mg route of administration: Intravenous experiment type: MULTIPLE co-administered: |
LEVOFLOXACIN unknown | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
7.8 mg/L |
500 mg 2 times / day multiple, oral dose: 500 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
LEVOFLOXACIN unknown | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
11.8 mg/L |
1000 mg 1 times / day multiple, oral dose: 1000 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
LEVOFLOXACIN unknown | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
8.85 mg/L |
1000 mg single, oral dose: 1000 mg route of administration: Oral experiment type: SINGLE co-administered: |
LEVOFLOXACIN unknown | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
2.04 mg/L |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
LEVOFLOXACIN unknown | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
6.3 mg/L |
500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
LEVOFLOXACIN unknown | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
49.6 mg × h/L |
500 mg 2 times / day multiple, intravenous dose: 500 mg route of administration: Intravenous experiment type: MULTIPLE co-administered: |
LEVOFLOXACIN unknown | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
59 mg × h/L |
500 mg 2 times / day multiple, oral dose: 500 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
LEVOFLOXACIN unknown | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
118 mg × h/L |
1000 mg 1 times / day multiple, oral dose: 1000 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
LEVOFLOXACIN unknown | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
111 mg × h/L |
1000 mg single, oral dose: 1000 mg route of administration: Oral experiment type: SINGLE co-administered: |
LEVOFLOXACIN unknown | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
19.88 mg × h/L |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
LEVOFLOXACIN unknown | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
55.3 mg × h/L |
500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
LEVOFLOXACIN unknown | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
7.6 h |
500 mg 2 times / day multiple, intravenous dose: 500 mg route of administration: Intravenous experiment type: MULTIPLE co-administered: |
LEVOFLOXACIN unknown | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
8.4 h |
500 mg 2 times / day multiple, oral dose: 500 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
LEVOFLOXACIN unknown | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
8.9 h |
1000 mg 1 times / day multiple, oral dose: 1000 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
LEVOFLOXACIN unknown | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
7.9 h |
1000 mg single, oral dose: 1000 mg route of administration: Oral experiment type: SINGLE co-administered: |
LEVOFLOXACIN unknown | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
5.97 h |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
LEVOFLOXACIN unknown | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
6.6 h |
500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
LEVOFLOXACIN unknown | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: Page: 19 |
unhealthy, mean 50 years n = 7537 Health Status: unhealthy Condition: infectious diseases Age Group: mean 50 years Sex: M+F Population Size: 7537 Sources: Page: 19 |
Disc. AE: Gastrointestinal disorder, Nausea... AEs leading to discontinuation/dose reduction: Gastrointestinal disorder (1.4%) Sources: Page: 19Nausea (0.6%) Vomiting (0.4%) Dizziness (0.3%) Headache (0.2%) |
500 mg 1 times / day steady, oral Recommended Dose: 500 mg, 1 times / day Route: oral Route: steady Dose: 500 mg, 1 times / day Sources: Page: 19 |
unhealthy, mean 50 years n = 7537 Health Status: unhealthy Condition: infectious diseases Age Group: mean 50 years Sex: M+F Population Size: 7537 Sources: Page: 19 |
Disc. AE: Gastrointestinal disorder, Nausea... AEs leading to discontinuation/dose reduction: Gastrointestinal disorder (1.4%) Sources: Page: 19Nausea (0.6%) Vomiting (0.4%) Dizziness (0.3%) Headache (0.2%) |
750 mg 1 times / day steady, oral Recommended Dose: 750 mg, 1 times / day Route: oral Route: steady Dose: 750 mg, 1 times / day Sources: Page: 19 |
unhealthy, mean 50 years n = 7537 Health Status: unhealthy Condition: infectious diseases Age Group: mean 50 years Sex: M+F Population Size: 7537 Sources: Page: 19 |
Disc. AE: Gastrointestinal disorder, Nausea... AEs leading to discontinuation/dose reduction: Gastrointestinal disorder (1.2%) Sources: Page: 19Nausea (0.6%) Vomiting (0.5%) Dizziness (0.3%) Headache (0.3%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Headache | 0.2% Disc. AE |
250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: Page: 19 |
unhealthy, mean 50 years n = 7537 Health Status: unhealthy Condition: infectious diseases Age Group: mean 50 years Sex: M+F Population Size: 7537 Sources: Page: 19 |
Dizziness | 0.3% Disc. AE |
250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: Page: 19 |
unhealthy, mean 50 years n = 7537 Health Status: unhealthy Condition: infectious diseases Age Group: mean 50 years Sex: M+F Population Size: 7537 Sources: Page: 19 |
Vomiting | 0.4% Disc. AE |
250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: Page: 19 |
unhealthy, mean 50 years n = 7537 Health Status: unhealthy Condition: infectious diseases Age Group: mean 50 years Sex: M+F Population Size: 7537 Sources: Page: 19 |
Nausea | 0.6% Disc. AE |
250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: Page: 19 |
unhealthy, mean 50 years n = 7537 Health Status: unhealthy Condition: infectious diseases Age Group: mean 50 years Sex: M+F Population Size: 7537 Sources: Page: 19 |
Gastrointestinal disorder | 1.4% Disc. AE |
250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: Page: 19 |
unhealthy, mean 50 years n = 7537 Health Status: unhealthy Condition: infectious diseases Age Group: mean 50 years Sex: M+F Population Size: 7537 Sources: Page: 19 |
Headache | 0.2% Disc. AE |
500 mg 1 times / day steady, oral Recommended Dose: 500 mg, 1 times / day Route: oral Route: steady Dose: 500 mg, 1 times / day Sources: Page: 19 |
unhealthy, mean 50 years n = 7537 Health Status: unhealthy Condition: infectious diseases Age Group: mean 50 years Sex: M+F Population Size: 7537 Sources: Page: 19 |
Dizziness | 0.3% Disc. AE |
500 mg 1 times / day steady, oral Recommended Dose: 500 mg, 1 times / day Route: oral Route: steady Dose: 500 mg, 1 times / day Sources: Page: 19 |
unhealthy, mean 50 years n = 7537 Health Status: unhealthy Condition: infectious diseases Age Group: mean 50 years Sex: M+F Population Size: 7537 Sources: Page: 19 |
Vomiting | 0.4% Disc. AE |
500 mg 1 times / day steady, oral Recommended Dose: 500 mg, 1 times / day Route: oral Route: steady Dose: 500 mg, 1 times / day Sources: Page: 19 |
unhealthy, mean 50 years n = 7537 Health Status: unhealthy Condition: infectious diseases Age Group: mean 50 years Sex: M+F Population Size: 7537 Sources: Page: 19 |
Nausea | 0.6% Disc. AE |
500 mg 1 times / day steady, oral Recommended Dose: 500 mg, 1 times / day Route: oral Route: steady Dose: 500 mg, 1 times / day Sources: Page: 19 |
unhealthy, mean 50 years n = 7537 Health Status: unhealthy Condition: infectious diseases Age Group: mean 50 years Sex: M+F Population Size: 7537 Sources: Page: 19 |
Gastrointestinal disorder | 1.4% Disc. AE |
500 mg 1 times / day steady, oral Recommended Dose: 500 mg, 1 times / day Route: oral Route: steady Dose: 500 mg, 1 times / day Sources: Page: 19 |
unhealthy, mean 50 years n = 7537 Health Status: unhealthy Condition: infectious diseases Age Group: mean 50 years Sex: M+F Population Size: 7537 Sources: Page: 19 |
Dizziness | 0.3% Disc. AE |
750 mg 1 times / day steady, oral Recommended Dose: 750 mg, 1 times / day Route: oral Route: steady Dose: 750 mg, 1 times / day Sources: Page: 19 |
unhealthy, mean 50 years n = 7537 Health Status: unhealthy Condition: infectious diseases Age Group: mean 50 years Sex: M+F Population Size: 7537 Sources: Page: 19 |
Headache | 0.3% Disc. AE |
750 mg 1 times / day steady, oral Recommended Dose: 750 mg, 1 times / day Route: oral Route: steady Dose: 750 mg, 1 times / day Sources: Page: 19 |
unhealthy, mean 50 years n = 7537 Health Status: unhealthy Condition: infectious diseases Age Group: mean 50 years Sex: M+F Population Size: 7537 Sources: Page: 19 |
Vomiting | 0.5% Disc. AE |
750 mg 1 times / day steady, oral Recommended Dose: 750 mg, 1 times / day Route: oral Route: steady Dose: 750 mg, 1 times / day Sources: Page: 19 |
unhealthy, mean 50 years n = 7537 Health Status: unhealthy Condition: infectious diseases Age Group: mean 50 years Sex: M+F Population Size: 7537 Sources: Page: 19 |
Nausea | 0.6% Disc. AE |
750 mg 1 times / day steady, oral Recommended Dose: 750 mg, 1 times / day Route: oral Route: steady Dose: 750 mg, 1 times / day Sources: Page: 19 |
unhealthy, mean 50 years n = 7537 Health Status: unhealthy Condition: infectious diseases Age Group: mean 50 years Sex: M+F Population Size: 7537 Sources: Page: 19 |
Gastrointestinal disorder | 1.2% Disc. AE |
750 mg 1 times / day steady, oral Recommended Dose: 750 mg, 1 times / day Route: oral Route: steady Dose: 750 mg, 1 times / day Sources: Page: 19 |
unhealthy, mean 50 years n = 7537 Health Status: unhealthy Condition: infectious diseases Age Group: mean 50 years Sex: M+F Population Size: 7537 Sources: Page: 19 |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/27853934/ Page: - |
inconclusive | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/19026171/ Page: - |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/27853934/ Page: - |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/27853934/ Page: - |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/27853934/ Page: - |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/27853934/ Page: - |
weak | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/19026171/ Page: - |
yes [IC50 210 uM] | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/16928358/ Page: - |
yes [IC50 6800 uM] | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/27853934/ Page: - |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/27853934/ Page: - |
yes |
Drug as victim
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/16474415/ Page: - |
PubMed
Title | Date | PubMed |
---|---|---|
Purification and inhibition by quinolones of DNA gyrases from Mycobacterium avium, Mycobacterium smegmatis and Mycobacterium fortuitum bv. peregrinum. | 1999 Sep |
|
Comparative antimicrobial activities of the newly synthesized quinolone WQ-3034, levofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex. | 2000 Feb |
|
In vitro susceptibilities of rapidly growing mycobacteria to telithromycin (HMR 3647) and seven other antimicrobials. | 2000 Jan |
|
Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones. | 2000 May |
|
Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials. | 2001 |
|
Activity of BMS284756 against 2,681 recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis: Report from The SENTRY Antimicrobial Surveillance Program (2000) in Europe, Canada and the United States. | 2001 Apr |
|
Enantioseparation of ofloxacin in urine by capillary electrokinetic chromatography using charged cyclodextrins as chiral selectors and assessment of enantioconversion. | 2001 Apr |
|
[Injectable quinolones]. | 2001 Apr |
|
Which fluoroquinolones are suitable for the treatment of urinary tract infections? | 2001 Apr |
|
Urothelial mucosal concentration of levofloxacin administered before transurethral resection: Is the mucosal concentration predictable? | 2001 Apr |
|
A nosocomial outbreak of fluoroquinolone-resistant Streptococcus pneumoniae. | 2001 Aug 15 |
|
Antimicrobial resistance of Streptococcus pneumoniae isolates in 1999 and 2000 in Madrid, Spain: a multicentre surveillance study. | 2001 Feb |
|
Efficacy of moxifloxacin, trovafloxacin, clinafloxacin and levofloxacin against intracellular Legionella pneumophila. | 2001 Feb |
|
In vitro activity of ketolides HMR 3004 and HMR 3647 and seven other antimicrobial agents against Corynebacterium diphtheriae. | 2001 Jan |
|
Measurement of the bactericidal activity of fluoroquinolones against Streptococcus pneumoniae using the bactericidal index method. | 2001 Jan |
|
[Levofloxacin adverse effects, data from clinical trials and pharmacovigilance]. | 2001 Jan-Feb |
|
Comparative in vitro bacteriostatic and bactericidal activity of trovafloxacin, levofloxacin and moxifloxacin against clinical and environmental isolates of Legionella spp. | 2001 Jul |
|
Comparative killing kinetics of the novel des-fluoro(6) quinolone BMS-284756, fluoroquinolones, vancomycin and beta-lactams. | 2001 Jul |
|
Comparison of in-vitro activities of SCH27899 and other antibiotics against Mycoplasma pneumoniae. | 2001 Jun |
|
Antidepressant, anxiogenic, and antinociceptive properties of levofloxacin in rats and mice. | 2001 Mar |
|
In vitro activity of four fluoroquinolones against Mycobacterium tuberculosis. | 2001 Mar |
|
Clinical perspectives on new antimicrobials: focus on fluoroquinolones. | 2001 Mar 15 |
|
Pharmacodynamics of moxifloxacin and levofloxacin against Staphylococcus aureus and Staphylococcus epidermidis in an in vitro pharmacodynamic model. | 2001 Mar 15 |
|
Comparative in vitro activity of the new quinolone gemifloxacin (SB-265805) with other fluoroquinolones against respiratory tract pathogens. | 2001 May |
|
Target site modifications and efflux phenotype in clinical isolates of Streptococcus pneumoniae from Hong Kong with reduced susceptibility to fluoroquinolones. | 2001 May |
|
Multi-laboratory assessment of the linezolid spectrum of activity using the Kirby-Bauer disk diffusion method: Report of the Zyvox Antimicrobial Potency Study (ZAPS) in the United States. | 2001 May-Jun |
|
Molecular epidemiology and mutations at gyrA and parC genes of ciprofloxacin-resistant Escherichia coli isolates from a Taiwan medical center. | 2001 Spring |
Sample Use Guides
The usual dose of LEVAQUIN tablets or oral solution is 250 mg, 500 mg, or 750 mg administered orally every 24 hours. The usual dose of LEVAQUIN Injection is 250 mg or 500 mg administered by slow infusion over 60 minutes every 24 hours or 750 mg administered by slow infusion over 90 minutes every 24 hours.
Nosocomial Pneumonia: 750 mg during 7–14 days
Community Acquired Pneumonia: 500 mg during 7–14 days
Community Acquired Pneumonia§ 750 mg during 5 days
Complicated Skin and Skin Structure Infections (SSSI) 750 mg during 7–14 days
Uncomplicated SSSI 500 mg during 7–10 days
Chronic Bacterial Prostatitis 500 mg during 28 days
Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) 750 mg during 5 days
Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) 250 mg during 10 days
Uncomplicated Urinary Tract Infection 250 mg 3 during days
Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB) 500 mg during 7 days
Acute Bacterial Sinusitis (ABS) 750 mg days or 500 mg during 10–14 days.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8077990
Levofloxacin was compared to ofloxacin and ciprofloxacin against > 6000 recent clinical isolates of Gram-positive and Gram-negative bacteria from six different countries. This international multicenter study demonstrated a high level of antibacterial activity of levofloxacin against all the members of Enterobacteriaceae [minimum inhibitory concentration (MIC)50s, < or = 0.03 to 0.12 mg/L] except Providencia rettgeri (MIC50, 2 mg/L), and Providencia stuartii (MIC50, 1 mg/L). Levofloxacin was also active against non-enteric Gram-negative bacilli, including Acinetobacter species (MIC50s, < or = 0.03 to 1 mg/L), Pseudomonas species (MIC50s, 0.5 to 1 mg/L) and Xanthomonas maltophilia (MIC50, 0.5 mg/L). Overall, levofloxacin inhibited 50% and 90% of all the tested strains at the concentrations of 0.12 and 4 mg/L, respectively. The activity of levofloxacin was generally two-fold greater than ofloxacin and equal to or slightly less potent than ciprofloxacin.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:44:23 GMT 2023
by
admin
on
Fri Dec 15 15:44:23 GMT 2023
|
Record UNII |
RIX4E89Y14
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
J01MA12
Created by
admin on Fri Dec 15 15:44:23 GMT 2023 , Edited by admin on Fri Dec 15 15:44:23 GMT 2023
|
||
|
WHO-ATC |
S01AX19
Created by
admin on Fri Dec 15 15:44:23 GMT 2023 , Edited by admin on Fri Dec 15 15:44:23 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
8028
Created by
admin on Fri Dec 15 15:44:23 GMT 2023 , Edited by admin on Fri Dec 15 15:44:23 GMT 2023
|
PRIMARY | |||
|
100000089067
Created by
admin on Fri Dec 15 15:44:23 GMT 2023 , Edited by admin on Fri Dec 15 15:44:23 GMT 2023
|
PRIMARY | |||
|
SUB08471MIG
Created by
admin on Fri Dec 15 15:44:23 GMT 2023 , Edited by admin on Fri Dec 15 15:44:23 GMT 2023
|
PRIMARY | |||
|
758709
Created by
admin on Fri Dec 15 15:44:23 GMT 2023 , Edited by admin on Fri Dec 15 15:44:23 GMT 2023
|
PRIMARY | |||
|
RIX4E89Y14
Created by
admin on Fri Dec 15 15:44:23 GMT 2023 , Edited by admin on Fri Dec 15 15:44:23 GMT 2023
|
PRIMARY | |||
|
63598
Created by
admin on Fri Dec 15 15:44:23 GMT 2023 , Edited by admin on Fri Dec 15 15:44:23 GMT 2023
|
PRIMARY | |||
|
DB01137
Created by
admin on Fri Dec 15 15:44:23 GMT 2023 , Edited by admin on Fri Dec 15 15:44:23 GMT 2023
|
PRIMARY | |||
|
C170539
Created by
admin on Fri Dec 15 15:44:23 GMT 2023 , Edited by admin on Fri Dec 15 15:44:23 GMT 2023
|
PRIMARY | |||
|
100986-85-4
Created by
admin on Fri Dec 15 15:44:23 GMT 2023 , Edited by admin on Fri Dec 15 15:44:23 GMT 2023
|
PRIMARY | |||
|
1546009
Created by
admin on Fri Dec 15 15:44:23 GMT 2023 , Edited by admin on Fri Dec 15 15:44:23 GMT 2023
|
PRIMARY | RxNorm | ||
|
6708
Created by
admin on Fri Dec 15 15:44:23 GMT 2023 , Edited by admin on Fri Dec 15 15:44:23 GMT 2023
|
PRIMARY | |||
|
149096
Created by
admin on Fri Dec 15 15:44:23 GMT 2023 , Edited by admin on Fri Dec 15 15:44:23 GMT 2023
|
PRIMARY | |||
|
SUB127353
Created by
admin on Fri Dec 15 15:44:23 GMT 2023 , Edited by admin on Fri Dec 15 15:44:23 GMT 2023
|
PRIMARY | |||
|
m8133
Created by
admin on Fri Dec 15 15:44:23 GMT 2023 , Edited by admin on Fri Dec 15 15:44:23 GMT 2023
|
PRIMARY | Merck Index | ||
|
DTXSID0041060
Created by
admin on Fri Dec 15 15:44:23 GMT 2023 , Edited by admin on Fri Dec 15 15:44:23 GMT 2023
|
PRIMARY | |||
|
RIX4E89Y14
Created by
admin on Fri Dec 15 15:44:23 GMT 2023 , Edited by admin on Fri Dec 15 15:44:23 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
TRANSPORTER -> INHIBITOR |
IC50
|
||
|
TARGET ORGANISM->INHIBITOR |
18 STRAINS; LESS THE 8 ng/mL for some strains; MIC range listed
MIC90
|
||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
TRANSPORTER -> INHIBITOR |
IC50
|
||
|
SALT/SOLVATE -> PARENT | |||
|
SUBSTANCE->BASIS OF STRENGTH | |||
|
SOLVATE->ANHYDROUS |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE LESS ACTIVE -> PARENT |
Less than 5% of an administered dose was recovered in the urine as the desmethyl and N-oxide metabolites
URINE
|
||
|
METABOLITE LESS ACTIVE -> PARENT |
Less than 5% of an administered dose was recovered in the urine as the desmethyl and N-oxide metabolites
URINE
|
||
|
METABOLITE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |